Stock 8329 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shenzhen Neptunus Interlong Bio-technique Company Limited

Equities

8329

CNE100000775

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 14/05/2024 BST 		5-day change 1st Jan Change
0.145 HKD -2.68% Intraday chart for Shenzhen Neptunus Interlong Bio-technique Company Limited -2.03% -11.59%
03-27 Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-15 Shenzhen Neptunus Interlong Bio-Technique Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 515.7 355.4 487.2 252.9 254.9 250.1
Enterprise Value (EV) 1 201.1 14.22 81.42 47.49 -2.506 -42.4
P/E ratio 10.7 x 5.95 x 13.3 x 7.03 x 4.69 x 10.4 x
Yield - - - - - -
Capitalization / Revenue 0.59 x 0.33 x 0.47 x 0.3 x 0.26 x 0.23 x
EV / Revenue 0.23 x 0.01 x 0.08 x 0.06 x -0 x -0.04 x
EV / EBITDA 2.52 x 0.15 x 0.88 x 0.78 x -0.02 x -0.56 x
EV / FCF -23.4 x 0.9 x 1.42 x 1.73 x -0.06 x -5.83 x
FCF Yield -4.27% 111% 70.4% 57.9% -1,723% -17.1%
Price to Book 0.74 x 0.47 x 0.61 x 0.3 x 0.29 x 0.28 x
Nbr of stocks (in thousands) 1,678,000 1,678,000 1,678,000 1,678,000 1,678,000 1,678,000
Reference price 2 0.3073 0.2118 0.2904 0.1507 0.1519 0.1491
Announcement Date 27/03/19 30/03/20 24/03/21 13/04/22 28/03/23 12/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 867.1 1,081 1,031 838.8 986.7 1,065
EBITDA 1 79.86 96.46 92.13 61.04 114.2 76.26
EBIT 1 61.81 75.96 69.29 35.75 85.42 48.18
Operating Margin 7.13% 7.03% 6.72% 4.26% 8.66% 4.52%
Earnings before Tax (EBT) 1 67.64 78.82 50.21 39.11 82.26 30.67
Net income 1 48.09 59.72 36.59 35.96 54.35 24.13
Net margin 5.55% 5.53% 3.55% 4.29% 5.51% 2.27%
EPS 2 0.0287 0.0356 0.0218 0.0214 0.0324 0.0144
Free Cash Flow 1 -8.593 15.75 57.32 27.51 43.17 7.27
FCF margin -0.99% 1.46% 5.56% 3.28% 4.37% 0.68%
FCF Conversion (EBITDA) - 16.32% 62.21% 45.06% 37.78% 9.53%
FCF Conversion (Net income) - 26.37% 156.64% 76.49% 79.43% 30.13%
Dividend per Share - - - - - -
Announcement Date 27/03/19 30/03/20 24/03/21 13/04/22 28/03/23 12/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 315 341 406 205 257 293
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -8.59 15.7 57.3 27.5 43.2 7.27
ROE (net income / shareholders' equity) 6.59% 7.65% 4.41% 3.73% 6.55% 1.44%
ROA (Net income/ Total Assets) 3.89% 4.5% 3.86% 1.84% 3.87% 2.1%
Assets 1 1,236 1,327 948.5 1,954 1,403 1,147
Book Value Per Share 2 0.4200 0.4500 0.4700 0.4900 0.5300 0.5400
Cash Flow per Share 2 0.1900 0.2300 0.2500 0.1400 0.1700 0.2200
Capex 1 27.6 32.9 31.3 11.7 19.7 15.2
Capex / Sales 3.18% 3.04% 3.04% 1.4% 2% 1.43%
Announcement Date 27/03/19 30/03/20 24/03/21 13/04/22 28/03/23 12/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED Stock Shenzhen Neptunus Interlong Bio-technique Company Limited
-11.59% 32M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.06% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 240B
NOVARTIS AG Stock Novartis AG
+10.16% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 203B
AMGEN INC. Stock Amgen Inc.
+8.12% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 8329 Stock
  4. Financials Shenzhen Neptunus Interlong Bio-technique Company Limited